New drug shows promise for rare immune disorder in early trial
NCT ID NCT06897358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called leniolisib in 20 people with common variable immunodeficiency (CVID), a condition that weakens the immune system. All participants will receive the drug for 6 months, starting at a low dose and increasing. The main goal is to check safety and tolerability, and to see if it helps control immune-related symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY (CVID) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
IIS La Fe
Valencia, Spain
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01805, United States
-
Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
National Institute of Health
Bethesda, Maryland, 20892, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.